Bank of New York Mellon
ALXO icon

Bank of New York Mellon’s ALX Oncology ALXO Stock Holding History

Bank of New York Mellon’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$494K Buy
+238,447
New +$427K ﹤0.01% 3758
2025
Q2 		– Sell
-89,199
Closed -$55.6K – 4143
2025
Q1 		$55.6K Sell
89,199
-804
-0.9% -$965 ﹤0.01% 4049
2024
Q4 		$150K Buy
90,003
+9,623
+12% +$14.8K ﹤0.01% 3996
2024
Q3 		$146K Sell
80,380
-24,586
-23% -$91.4K ﹤0.01% 3964
2024
Q2 		$633K Buy
104,966
+25,199
+32% +$310K ﹤0.01% 3447
2024
Q1 		$889K Sell
79,767
-6,539
-8% -$91.8K ﹤0.01% 3215
2023
Q4 		$1.29M Buy
86,306
+14,256
+20% +$135K ﹤0.01% 3061
2023
Q3 		$346K Sell
72,050
-40
-0.1% -$217 ﹤0.01% 3745
2023
Q2 		$541K Buy
72,090
+3,065
+4% +$20.1K ﹤0.01% 3546
2023
Q1 		$312K Sell
69,025
-634
-0.9% -$4.8K ﹤0.01% 3724
2022
Q4 		$785K Sell
69,659
-61
-0.1% -$685 ﹤0.01% 3320
2022
Q3 		$667K Buy
69,720
+6,620
+10% +$77.2K ﹤0.01% 3408
2022
Q2 		$510K Sell
63,100
-10,993
-15% -$120K ﹤0.01% 3571
2022
Q1 		$1.25M Sell
74,093
-4,201
-5% -$71.7K ﹤0.01% 3172
2021
Q4 		$1.68M Sell
78,294
-11,818
-13% -$510K ﹤0.01% 3093
2021
Q3 		$6.66M Buy
90,112
+17,510
+24% +$1.17M ﹤0.01% 2351
2021
Q2 		$3.97M Buy
72,602
+7,330
+11% +$439K ﹤0.01% 2601
2021
Q1 		$4.81M Buy
65,272
+5,698
+10% +$448K ﹤0.01% 2458
2020
Q4 		$5.14M Buy
59,574
+35,845
+151% +$2.16M ﹤0.01% 2345
2020
Q3 		$896K Buy
+23,729
New +$933K ﹤0.01% 3182

Other funds holding ALXO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
AC
AXQ Capital Jersey City, New Jersey $920M AUM 18.71% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

Bank of New York Mellon's ALXO Position: Q2 2026 in Review

Bank of New York Mellon opened a new position in ALX Oncology (ALXO) in Q2 2026: 238,447 shares worth $494K. The stake represents ﹤0.01% of the portfolio and ranks #3758 among its holdings. This is a return to the name: Bank of New York Mellon previously reported a position in ALXO as recently as Q1 2025.

Bank of New York Mellon first reported a position in ALXO in Q3 2020 and has held it in 20 quarters since. The position peaked at $6.66M in Q3 2021. 34 funds tracked by Wall St. Rank hold ALXO as of Q2 2026.

  • Bank of New York Mellon held 238,447 shares of ALX Oncology worth $494K as of Q2 2026.
  • ALX Oncology was a new Bank of New York Mellon position in Q2 2026.
  • ALX Oncology made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #3758 holding.
  • Bank of New York Mellon first reported a position in ALX Oncology in Q3 2020 and has held it in 20 quarters since.
  • Bank of New York Mellon's ALX Oncology position peaked at $6.66M in Q3 2021.
  • 34 funds tracked by Wall St. Rank held ALX Oncology as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.